Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

2.1 Pembrolizumab (Keytruda, Merck Sharp & Dohme) has a marketing authorisation for 'the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 £2,630 per 100‑mg vial (excluding VAT; company submission).

2.4 The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.